title: First-line treatment for patients with CML in chronic phase: second-generation TKIs are the therapy of choice.
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, USA.
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
mesh_terms: D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
chemical_list: D047428:Protein Kinase Inhibitors